Mauna Kea Technologies
  • Physicians
    • Overview
    • Cellvizio system
    • Education
    • Reimbursement
    • GastroEnterology
    • Barrett’s Esophagus
    • Pancreatic Cysts
    • Gastric Disease
    • Inflammatory Bowel Diseases
    • Irritable Bowel Syndrome
    • Bilio-Pancreatic Strictures
    • Colorectal Lesions
    • Pulmonology
    • Lung Nodules
    • Covid-19
    • Urology
  • Investors
  • About us
    • Our story
    • Team
    • Board of Directors
    • Leadership
    • Join Us
    • Commercial Network
  • News & events
  • US
  • INT
  • FR
Contact

News & Events

Lung news and event.png
NEWS - Cellvizio
May 18, 2022

On Target Laboratories and Mauna Kea Technologies Demonstrate Intraprocedural Targeted Detection of Lung Cancer with a Molecular Imaging Agent

Discover
MKT Card.png
NEWS - Cellvizio
Apr 21, 2022

Mauna Kea Technologies publishes Q1 2022 sales and its 2021 financial results

Discover
MKT Card.png
NEWS - Cellvizio
Apr 12, 2022

Mauna Kea Technologies Announces First of Its Kind U.S. FDA 510(k) Clearance for Use of Cellvizio in a New Category of Molecular Imaging-guided Endoscopic, Laparoscopic, Needle-Based Procedures

Discover
MKT Card.png
EVENTS - Cellvizio
Mar 17, 2022

Mauna Kea Technologies to Present at 32nd Annual Oppenheimer Healthcare Conference on March 17, 2022

Discover
MKT Card.png
NEWS - Cellvizio
Mar 8, 2022

On Target Laboratories and Mauna Kea Technologies Announce a Novel Clinical Research and Product Development Collaboration

Discover
Lung news and event.png
NEWS - Cellvizio
Feb 22, 2022

Mauna Kea Technologies Announces Start of Enrollment in Peripheral Lung Cancer Multi-Center Clinical Trial

Discover
See more
  • Facebook
  • Twitter
  • Linkedin
  • Youtube
  • Legal notice
  • Join Us
  • Contact us
  • Cellvizio.net
  • DiagnosingBarretts.org
  • DiagnosingPancreaticCysts.org
Mauna Kea Technologies